INCY News and Press, Incyte Corporation From 09/05/22

Summary This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion in Assets Under Management. From 1/2/2016 to date investing in all 50 stocks, equally weighted, would have produced a total retu...

The US FDA has approved Incyte's ( NASDAQ: INCY ) Pemazyre (pemigatinib) for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement. The selective fibroblast growth factor receptor (FGFR) inhibitor was approv...

– T his marks the second indication for Pemazyre, which received accelerated FDA approval in 2020 for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearra...

Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2022 European Academy of Dermatology and Venereology (EADV) Congress, held September 7-10, 2022, in Milan and virtually. “We are excite...

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. After the Q1-2022 13F filings the consensus holdings were updated, 10 stocks were removed and 8 added from the univ...

Incyte Corporation (INCY) Q2 2022 Earnings Conference Call Augut 02, 2022 8:00 AM ET Company Participants Christine Chiou – Head of Investor Relations Hervé Hoppenot – Chairman, President and Chief Executive Officer Barry Flannelly – Exe...

Incyte ( NASDAQ: INCY ) saw its Q2 net income rise ~27% year over year to ~$226.4M as it beat on the top and bottom lines . Non-GAAP basic EPS of $1.02 compared to $0.81 in Q2 2021. Revenue of $911.4M was ~29% year-over-year increase. This was driven by a 13% incre...

The following slide deck was published by Incyte Corporation in conjunction with their 2022 Q2 earnings call. For further details see: Incyte Corporation 2022 Q2 - Results - Earnings Call Presentation

Incyte press release ( NASDAQ: INCY ): Q2 Non-GAAP EPS of $1.01 beats by $0.27 . Revenue of $911.4M (+29.1% Y/Y) beats by $93.15M . Jakafi net product revenue guidance range of $2.36B to $2.4B for 2022 (prior $2.33B - $2.4B). “The second quarter...

Total revenues increased 29% year-over-year (Y/Y) to $911 million; total product revenues of $664 million (+15% Y/Y) Jakafi ® (ruxolitinib) net product revenues of $598 million in Q2’22 (+13% Y/Y) driven by volume growth; raising the bottom end of full year g...